|Bid||108.59 x 900|
|Ask||108.41 x 800|
|Day's Range||108.17 - 109.72|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||37.21|
|Earnings Date||Oct 28, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||5.20 (4.54%)|
|Ex-Dividend Date||Jul 14, 2021|
|1y Target Est||125.96|
Is AbbVie stock a buy as shares make a comeback on promising news for its drugs, Skyrizi and Rinvoq, in inflammatory conditions?
AbbVie (ABBV) is expected to have witnessed a recovery in demand trends of new drugs amid the receding impact of the pandemic. However, sales of physician-administered drugs are likely to have been hurt by the residual impact.
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.